A case report on the long-term survival of a patient with HER2-positive metastatic gastric adenocarcinoma and a short review of the current literature

被引：1

作者：

Puhr, Hannah Christina ^{[1
,2
]}

Ilhan-Mutlu, Ayseguel ^{[1
,2
]}

机构：

[1] Med Univ Vienna, Div Oncol, Dept Med 1, Vienna, Austria

[2] Med Univ Vienna, Upper Gastrointestinal Tumors Unit, Comprehens Canc Ctr Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria

来源：

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY | 2020年 / 13卷 / 04期

关键词：

Gastric cancer; Upper GI cancer; HER2; Trastuzumab; Ramucirumab; GASTROESOPHAGEAL JUNCTION CANCER; HER2; STATUS; OPEN-LABEL; TRASTUZUMAB; CHEMOTHERAPY; ESOPHAGEAL; PROGNOSIS;

D O I：

10.1007/s12254-020-00649-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The prognosis of patients with metastatic gastroesophageal cancer remains poor despite numerous promising clinical trials, and the clinical benefit of systemic therapies is under critical review. This case report of a patient with human epidermal growth factor receptor 2 (HER2)-positive metastatic gastric adenocarcinoma is an impulse for the importance of individual decision making and molecular guided treatment options.

引用

页码：453 / 458

页数：6

共 32 条

[1] Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial [J].

Al-Batran, Salah-Eddin ;

Homann, Nils ;

Pauligk, Claudia ;

Goetze, Thorsten O. ;

Meiler, Johannes ;

Kasper, Stefan ;

Kopp, Hans-Georg ;

Mayer, Frank ;

Haag, Georg Martin ;

Luley, Kim ;

Lindig, Udo ;

Schmiegel, Wolff ;

Pohl, Michael ;

Stoehlmacher, Jan ;

Folprecht, Gunnar ;

Probst, Stephan ;

Prasnikar, Nicole ;

Fischbach, Wolfgang ;

Mahlberg, Rolf ;

Trojan, Joerg ;

Koenigsmann, Michael ;

Martens, Uwe M. ;

Thuss-Patience, Peter ;

Egger, Matthias ;

Block, Andreas ;

Heinemann, Volker ;

Illerhaus, Gerald ;

Moehler, Markus ;

Schenk, Michael ;

Kullmann, Frank ;

Behringer, Dirk M. ;

Heike, Michael ;

Pink, Daniel ;

Teschendorf, Christian ;

Loehr, Carmen ;

Bernhard, Helga ;

Schuch, Gunter ;

Rethwisch, Volker ;

von Weikersthal, Ludwig Fischer ;

Hartmann, Joerg T. ;

Kneba, Michael ;

Daum, Severin ;

Schulmann, Karsten ;

Weniger, Joerg ;

Belle, Sebastian ;

Gaiser, Timo ;

Oduncu, Fuat S. ;

Guentner, Martina ;

Hozaeel, Wael ;

Reichart, Alexander .

LANCET, 2019, 393 (10184) :1948-1957

[2] Analysis of symptoms and functional HRQoL scales in TAGS, a phase III trial of trifluridine/tipiracil (FTD/TPI) in metastatic gastric cancer (mGC). [J].

Alsina, Maria ;

Tabernero, Josep ;

Shitara, Kohei ;

Doi, Toshihiko ;

Dvorkin, Mikhail ;

Mansoor, Wasat ;

Arkenau, Hendrik-Tobias ;

Prokharau, Aliaksandr ;

Ghidini, Michele ;

Faustino, Catia ;

Gorbunova, Vera ;

Zhavrid, Edvard ;

Nishikawa, Kazuhiro ;

Ando, Takayuki ;

Yalcin, Suayib ;

Van Cutsem, Eric ;

Skanji, Donia ;

Leger, Catherine ;

Sabater, Javier ;

Ilson, David H. .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

[3]

[Anonymous], 2019, SEER CANC STAT FACTS

[4]

Bang YJ, 2010, LANCET, V376, P1302

[5] A randomized, open-label, phase III study of lapatinib in combination with weekly paclitaxel versus weekly paclitaxel alone in the second-line treatment of HER2 amplified advanced gastric cancer (AGC) in Asian population: Tytan study [J].

Bang, Yung-Jue .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)

[6] ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers [J].

Cherny, N. I. ;

Sullivan, R. ;

Dafni, U. ;

Kerst, J. M. ;

Sobrero, A. ;

Zielinski, C. ;

Piccart, M. J. ;

Bogaerts, J. ;

Tabernero, J. ;

Latino, N. J. ;

de Vries, E. G. E. .

ESMO OPEN, 2016, 1 (05)

[7] Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study [J].

De Vita, Ferdinando ;

Borg, Christophe ;

Farina, Gabriella ;

Geva, Ravit ;

Carton, Iris ;

Cuku, Hera ;

Wei, Ran ;

Muro, Kei .

FUTURE ONCOLOGY, 2019, 15 (23) :2723-2731

[8] Efficacy and safety of trastuzumab as maintenance or palliative therapy in advanced HER2-positive gastric cancer [J].

Fu, Xiaomin ;

Zhang, Yong ;

Yang, Jing ;

Qi, Yalong ;

Ming, Yue ;

Sun, Miaomiao ;

Shang, Yiman ;

Yang, Yonghao ;

Zhu, Xiaoyan ;

Gao, Quanli .

ONCOTARGETS AND THERAPY, 2018, 11 :6091-6100

[9] Optimal regimen of trastuzumab in combination with oxaliplatin/capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial [J].

Gong, Jifang ;

Liu, Tianshu ;

Fan, Qingxia ;

Bai, Li ;

Bi, Feng ;

Qin, Shukui ;

Wang, Jinwan ;

Xu, Nong ;

Cheng, Ying ;

Bai, Yuxian ;

Liu, Wei ;

Wang, Liwei ;

Shen, Lin .

BMC CANCER, 2016, 16

[10] Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC-A Randomized Phase III Trial [J].

Hecht, J. Randolph ;

Bang, Yung-Jue ;

Qin, Shukui K. ;

Chung, Hyun C. ;

Xu, Jianming M. ;

Park, Joon O. ;

Jeziorski, Krzysztof ;

Shparyk, Yaroslav ;

Hoff, Paulo M. ;

Sobrero, Alberto ;

Salman, Pamela ;

Li, Jin ;

Protsenko, Svetlana A. ;

Wainberg, Zev A. ;

Buyse, Marc ;

Afenjar, Karen ;

Houe, Vincent ;

Garcia, Agathe ;

Kaneko, Tomomi ;

Huang, Yingjie ;

Khan-Wasti, Saba ;

Santillana, Sergio ;

Press, Michael F. ;

Slamon, Dennis .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (05) :443-+

← 1 2 3 4 →